Jonathan S. Wolin
Known title: Chief of Staff, CCO & GCCIK: 0001787587
Jonathan S. Wolin's purchase track record
Jonathan S. Wolin has only 1 open-market purchase with a full 6 months of price history after it -- too few to call a track record yet.
| Purchase | Stock | Amount | 3 months | 6 months | S&P 500, 6 mo. |
|---|---|---|---|---|---|
| 12/31/2022 | JAGX | $10 | -91.1% | -91.8% | +16.5% |
Computed by MarketWall from SEC Form 4 filings and daily closing prices (close on the purchase date to the close about 3 and 6 months later). Companies that have since delisted are not included. Past results, not investment advice.
Associated companies
Transaction History
| JAGX | ▲ Buy | Grant | 11,740 | $0 | 12/11/2025 | View on chart |
| JAGX | ▲ Buy | Grant | 4,922 | $0 | 10/8/2024 | View on chart |
| JAGX | ▲ Buy | Option Exercise | 871 | — | 5/17/2024 | View on chart |
| JAGX | ▲ Buy | Option Exercise | 89 | — | 4/5/2024 | View on chart |
| JAGX | ▲ Buy | Grant | 196,628 | $0 | 8/14/2023 | View on chart |
| JAGX | ▲ Buy | Option Exercise | 871 | — | 5/17/2023 | View on chart |
| JAGX | ▲ Buy | Option Exercise | 88 | — | 4/5/2023 | View on chart |
| JAGX | ▲ Buy | Open Market | 317 | $10 | 12/31/2022 | View on chart |
| JAGX | ▲ Buy | Option Exercise | 6,666 | — | 4/5/2022 | View on chart |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 3, 2026
JAGX Announces Stock Dividend, Crofelemer Study Presentations
Jaguar Health announced a special stock dividend, giving shareholders additional shares. The company also has two Crofelemer studies accepted for presentation at the American College of Gastroenterology meetings, providing early data on the drug’s use in short bowel syndrome. These events highlight ongoing progress in Jaguar’s product pipeline and shareholder value.
JAGX Announces Stock Dividend, Crofelemer Study Presentations. Jaguar Health announced a special stock dividend, giving shareholders additional shares. The company also has two Crofelemer studies accepted for presentation at the American College of Gastroenterology meetings, providing early data on the drug’s use in short bowel syndrome. These events highlight ongoing progress in Jaguar’s product pipeline and shareholder value.